Macrogenics (MGNX) Gains from Investment Securities (2012 - 2026)
Macrogenics (MGNX) reported Gains from Investment Securities of $218000.0 for Q1 2026, down 22.7% year-over-year from $282000.0 in Q1 2025, and up 3533.33% quarter-over-quarter from $6000.0 in Q4 2025.
Macrogenics (MGNX) Gains from Investment Securities (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has 13 years of Gains from Investment Securities data on file, last reported at $218000.0 in Q1 2026.
- Gains from Investment Securities for Q1 2026 came in at $218000.0, down 22.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $224000.0 (down 38.8% YoY), and the FY2025 annual result was $288000.0, down 88.36% from the prior year.
- Gains from Investment Securities improved to $218000.0 in Q1 2026 per MGNX's latest filing, from $6000.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $2.4 million in Q1 2024 and troughed at -$2.9 million in Q4 2022.
- A 5-year average of -$20250.0 and a median of $40000.0 in 2024 frame the typical range for Gains from Investment Securities.
- The sharpest annual moves came in 2024 and 2025: Gains from Investment Securities jumped 2556.67% in 2024, then plunged 4800.0% in 2025.
- A 5-year view of Gains from Investment Securities shows it stood at -$2.9 million in 2022, then soared by 74.83% to -$729000.0 in 2023, then jumped by 100.55% to $4000.0 in 2024, then soared by 50.0% to $6000.0 in 2025, then soared by 3533.33% to $218000.0 in 2026.
- Business Quant data shows MGNX's Gains from Investment Securities at $218000.0 in Q1 2026, $6000.0 in Q4 2025, and $282000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Macrogenics | 260.14 Mn | 193.63 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 218,000.00 |
| Mar 31, 2026 | 218,000.00 |
| Dec 31, 2025 | 6,000.00 |
| Dec 31, 2025 | 6,000.00 |
| Sep 30, 2025 | 282,000.00 |
| Sep 30, 2025 | 282,000.00 |
| Jun 30, 2025 | -282,000.00 |
| Jun 30, 2025 | -282,000.00 |
| Mar 31, 2025 | 282,000.00 |
| Mar 31, 2025 | 282,000.00 |
| Dec 31, 2024 | 4,000.00 |
| Dec 31, 2024 | 4,000.00 |
| Sep 30, 2024 | 74,000.00 |
| Sep 30, 2024 | 74,000.00 |
| Jun 30, 2024 | 6,000.00 |
| Jun 30, 2024 | 6,000.00 |
| Mar 31, 2024 | 2.39 Mn |
| Mar 31, 2024 | 2.39 Mn |
| Dec 31, 2023 | -729,000.00 |
| Dec 31, 2023 | -729,000.00 |